Martha Newcomb
Psychiatric/Mental Health · Fort Branch, INNPI 1194331371
Payments from drug & device makers
Across 151 payments — averaging $16.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$713
- AbbVie$325
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$263
- Indivior Inc.$165
- Takeda Pharmaceuticals U.S.A., Inc.$161
- Alkermes, Inc.$159
- plus $677 from 13 others
What the payments were for
- Food & beverage$2,41698%
- Education$472%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$2,463 in reported general payments places this provider in the 75th percentile of 729 psychiatric/mental health providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 15 | $118,113 |
| VraylarCariprazine Hcl | 28 | $37,780 |
| RexultiBrexpiprazole | 18 | $25,357 |
| QuviviqDaridorexant Hcl | 13 | $6,044 |
| VyvanseLisdexamfetamine Dimesylate | 11 | $3,936 |
| Lurasidone Hcl | 30 | $3,317 |
| Atomoxetine Hcl | 20 | $3,169 |
| Duloxetine Hcl | 39 | $1,621 |
| Doxepin Hcl | 15 | $1,347 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 21 | $1,178 |
| Aripiprazole | 44 | $956 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 33 | $873 |
| Prazosin Hcl | 38 | $578 |
| Buspirone Hcl | 35 | $292 |
| Hydroxyzine Pamoate | 20 | $284 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $35 | $118,11315 claims |
| AbbVieVraylar | $325 | $37,78028 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $713 | $25,35718 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $29 | $6,04413 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $161 | $3,93611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 729 psychiatric/mental health providers in Indiana.
Other psychiatric/mental health in Fort Branch
- Brooke KempfTerre Haute$1.1M
- Gerald LewisMerrillville$336K
- Lauren LutzColumbus$320K
- Sonya RuedlingerIndianapolis$134K
- Trina GreenwaldMarion$107K
- Paul DuncanJeffersonville$46K
- Morgan StamperConnersville$42K
- Jennifer JimenezUnion Mills$37K
- Savannah MullinsClarksville$31K
- Sharon ClevengerFort Wayne$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.